Press Releases

Date Title and Summary Additional Formats
Toggle Summary Radius Health Announces Third Quarter 2018 Operating Results and Financial Guidance for FY 2018 and FY 2019
TYMLOS® U.S. net sales continued to increase in the third quarter of 2018, totaling $27.6 million. 2019 Medicare Part D coverage for TYMLOS increased from 44% to 64%  Elacestrant Phase 3 study to target a broader patient population, comprised of 2 nd and 3 rd line ER+ mBC, with potential for
View HTML
Toggle Summary Radius Health to Announce Third Quarter 2018 Financial Results, Host Conference Call and Live Webcast on November 1, 2018
WALTHAM, Mass. , Oct. 12, 2018 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its third quarter financial results on Thursday, November 1, 2018 . The Company will host a conference call and live audio webcast at 8:00 a.m.
View HTML
Toggle Summary Radius Health Announces Latest 2019 Medicare Part D Coverage for TYMLOS® (abaloparatide) Injection
TYMLOS is now covered for 64% of Medicare Part D insured lives WALTHAM, Mass. , Oct. 03, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in
View HTML
Toggle Summary Radius Health to Present at the Leerink Partners Oncology Roundtable Series
WALTHAM, Mass. , Sept. 28, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS) announced today that Jesper Høiland, President and CEO and Charles Morris , Chief Medical Officer of the Company will present a corporate update at the Leerink Partners Oncology Roundtable Series on Wednesday,
View HTML
Toggle Summary Radius Health to Present Data on Abaloparatide at ASBMR 2018 Annual Meeting
WALTHAM, Mass. , Sept. 24, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), a science-driven fully integrated biopharmaceutical company committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology, today announced it will
View HTML
Toggle Summary Radius Health to Present at the Morgan Stanley 16th Annual Global Health Care Conference
WALTHAM, Mass. , Sept. 11, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS) announced today that Jesper Høiland, President and CEO, and Pepe Carmona , Chief Financial Officer of the Company, will present a corporate update at the Morgan Stanley 16th Annual Global Health Care Conference
View HTML
Toggle Summary Radius Health Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass. , Sept. 06, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq:RDUS) today announced that the Company’s Board of Directors granted Dr. Charles Morris , in connection with his appointment as the Company’s Chief Medical Officer, an option to purchase
View HTML
Toggle Summary Radius Health Appoints Dr. Charles Morris as Chief Medical Officer
WALTHAM, Mass. , Sept. 04, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) today announced the appointment of Dr. Charles Morris as Chief Medical Officer. Dr. Morris will oversee and lead all clinical development, regulatory and medical affairs strategies and
View HTML
Toggle Summary Radius Health Reports Second Quarter 2018 Financial and Operating Results and Provides Business Update
Second quarter 2018 TYMLOS sales increase to $22.6 million, a 56% increase  over the first quarter of 2018 TYMLOS' share in the U.S. anabolic osteoporosis market increased to an average of 19% in the second quarter from 13% in the prior quarter Radius maintains its 19-21% average 2018 U.S.
View HTML
Toggle Summary Radius Health Provides Update on Appeal of CHMP Opinion for Abaloparatide-SC
WALTHAM, Mass., July 24, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology, today announced that
View HTML